The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer

References

• Osman M. The role of neoadjuvant chemotherapy in the management of locally advanced cervix cancer: a systematic review. Oncol Rev 2014; 8:250; PMID:25992238; http://dx.doi.org/10.4081/oncol.2014.250
   PubMedGoogle Scholar
• Denny L. Cervical cancer: prevention and treatment. Discov Med 2012; 14:125-31; PMID:22935209
   PubMed Web of Science ®Google Scholar
• Kokka F, Bryant A, Brockbank E, Powell M, Oram D. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev 2015; 4:CD010260; PMID:25847525
   PubMedGoogle Scholar
• Taylor SS, Scott MI, Holland AJ. The spindle checkpoint: a quality control mechanism which ensures accurate chromosome segregation. Chromosome Res 2004; 12:599-616; PMID:15289666; http://dx.doi.org/10.1023/B:CHRO.0000036610.78380.51
   PubMed Web of Science ®Google Scholar
• Lassus H, Staff S, Leminen A, Isola J, Butzow R. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol Oncol 2011; 120:11-7; PMID:20937525; http://dx.doi.org/10.1016/j.ygyno.2010.09.003
   PubMed Web of Science ®Google Scholar
• Wang J, Yang S, Zhang H, Song Y, Zhang X, Qian H, Han X, Shi Y. Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncol Rep 2011; 26:23-32; PMID:21479365; http://dx.doi.org/10.3892/or.2011.1250
   PubMed Web of Science ®Google Scholar
• Gully CP, Velazquez-Torres G, Shin JH, Fuentes-Mattei E, Wang E, Carlock C, Chen J, Rothenberg D, Adams HP, Choi HH, et al. Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci U S A 2012; 109:E1513-22; PMID:22611192; http://dx.doi.org/10.1073/pnas.1110287109
   PubMed Web of Science ®Google Scholar
• Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998; 17:3052-65; PMID:9606188; http://dx.doi.org/10.1093/emboj/17.11.3052
   PubMed Web of Science ®Google Scholar
• Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, Saya H. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003; 278:51786-95; PMID:14523000; http://dx.doi.org/10.1074/jbc.M306275200
   PubMed Web of Science ®Google Scholar
• Zhou S-F, Li J-P, Yang Y-X, Liu Q-L, Pan S, He Z, Zhang X, Yang T, Chen X-W, Wang D, et al. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Drug Des Devel Ther 2015:1627; PMID:25834401; http://dx.doi.org/10.2147/DDDT.S75378
   PubMed Web of Science ®Google Scholar
• Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10:262-7; PMID:14981513; http://dx.doi.org/10.1038/nm1003
   PubMed Web of Science ®Google Scholar
• Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, Zhang H, Wang H, Adams HP, Jiang S, Chakraborty SN, et al. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell 2012; 21:196-211; PMID:22340593; http://dx.doi.org/10.1016/j.ccr.2011.12.025
   PubMed Web of Science ®Google Scholar
• Oh ET, Byun MS, Lee H, Park MT, Jue DM, Lee CW, Lim BU, Park HJ. Aurora-a contributes to radioresistance by increasing NF-kappaB DNA binding. Radiat Res 2010; 174:265-73; PMID:20726719; http://dx.doi.org/10.1667/RR2017.1
   PubMed Web of Science ®Google Scholar
• Wu CC, Yu CT, Chang GC, Lai JM, Hsu SL. Aurora-A promotes gefitinib resistance via a NF-kappaB signaling pathway in p53 knockdown lung cancer cells. Biochem Biophys Res Commun 2011; 405:168-72; PMID:21216229; http://dx.doi.org/10.1016/j.bbrc.2011.01.001
   PubMed Web of Science ®Google Scholar
• Opyrchal M, Salisbury JL, Zhang S, McCubrey J, Hawse J, Goetz MP, Lomberk GA, Haddad T, Degnim A, Lange C, et al. Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ERalpha expression in initially ERalpha+ breast cancer cells. PloS One 2014; 9:e96995; PMID:24816249; http://dx.doi.org/10.1371/journal.pone.0096995
   PubMedGoogle Scholar
• Xu J, Yue CF, Zhou WH, Qian YM, Zhang Y, Wang SW, Liu AW, Liu Q. Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis. J Transl Med 2014; 12:200; PMID:25082261; http://dx.doi.org/10.1186/1479-5876-12-200
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun H, Wang Z, Liu M, Qi Z, Meng J, Sun J, Yang G. Aurora-A: a potential DNA repair modulator. Tumor Biol 2013; 35:2831-6; PMID:24277377; http://dx.doi.org/10.1007/s13277-013-1393-8
   PubMed Web of Science ®Google Scholar
• Moretti L, Niermann K, Schleicher S, Giacalone NJ, Varki V, Kim KW, Kopsombut P, Jung DK, Lu B. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation. Int J Radiat Oncol Biol Phys 2011; 80:1189-97; PMID:21514073; http://dx.doi.org/10.1016/j.ijrobp.2011.01.060
   PubMed Web of Science ®Google Scholar
• Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010; 10:825-41; PMID:21102634; http://dx.doi.org/10.1038/nrc2964
   PubMed Web of Science ®Google Scholar
• Kumari G, Ulrich T, Krause M, Finkernagel F, Gaubatz S. Induction of p21CIP1 protein and cell cycle arrest after inhibition of Aurora B kinase is attributed to aneuploidy and reactive oxygen species. J Biol Chem 2014; 289:16072-84; PMID:24782314; http://dx.doi.org/10.1074/jbc.M114.555060
   PubMed Web of Science ®Google Scholar
• Mori N, Ishikawa C, Senba M, Kimura M, Okano Y. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas. Biochem Pharmacol 2011; 81:1106-15; PMID:21371446; http://dx.doi.org/10.1016/j.bcp.2011.02.010
   PubMed Web of Science ®Google Scholar
• Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007; 13:3682-8; PMID:17575233; http://dx.doi.org/10.1158/1078-0432.CCR-06-2979
   PubMed Web of Science ®Google Scholar
• Tyler RK, Shpiro N, Marquez R, Eyers PA. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle 2007; 6:2846-54; PMID:18032922; http://dx.doi.org/10.4161/cc.6.22.4940
   PubMed Web of Science ®Google Scholar
• Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, et al. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia 2013; 27:113-7; PMID:22772060; http://dx.doi.org/10.1038/leu.2012.186
   PubMed Web of Science ®Google Scholar
• Yao R, Zheng J, Zheng W, Gong Y, Liu W, Xing R. VX680 suppresses the growth of HepG2 cells and enhances the chemosensitivity to cisplatin. Oncol Lett 2014; 7:121-4; PMID:24348832; http://dx.doi.org/10.3892/ol.2013.1648
   Google Scholar
• Cheung CH, Sarvagalla S, Lee JY, Huang YC, Coumar MS. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 – 2013). Expert opin Ther Pat 2014; 24:1021-38; PMID:24965505; http://dx.doi.org/10.1517/13543776.2014.931374
   PubMed Web of Science ®Google Scholar
• Liu H, He J, Yang J. Tumor cell p38 MAPK: A trigger of cancer bone osteolysis. Cancer Cell Microenviron 2015; 2; PMID:26029733
   PubMedGoogle Scholar
• Kim HG, Shi C, Bode AM, Dong Z. p38alpha MAPK is required for arsenic-induced cell transformation. Mol carcinog 2015; 55:910-7 PMID:25969347; http://dx.doi.org/10.1002/mc.22331
   PubMed Web of Science ®Google Scholar
• Plotnikov A, Zehorai E, Procaccia S, Seger R. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta 2011; 1813:1619-33; PMID:21167873; http://dx.doi.org/10.1016/j.bbamcr.2010.12.012
   PubMed Web of Science ®Google Scholar
• Furukawa T. Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer. Front Oncol 2015; 5:23; PMID:25699241; http://dx.doi.org/10.3389/fonc.2015.00023
   PubMed Web of Science ®Google Scholar
• Fu Y, O'Connor LM, Shepherd TG, Nachtigal MW. The p38 MAPK inhibitor, PD169316, inhibits transforming growth factor beta-induced Smad signaling in human ovarian cancer cells. Biochem Biophys Res Commun 2003; 310:391-7; PMID:14521923; http://dx.doi.org/10.1016/j.bbrc.2003.09.021
   PubMed Web of Science ®Google Scholar
• Tsuchiya T, Tsuno NH, Asakage M, Yamada J, Yoneyama S, Okaji Y, Sasaki S, Kitayama J, Osada T, Takahashi K, et al. Apoptosis induction by p38 MAPK inhibitor in human colon cancer cells. Hepato-gastroenterology 2008; 55:930-5; PMID:18705300
   PubMed Web of Science ®Google Scholar
• Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007; 11:191-205; PMID:17292829; http://dx.doi.org/10.1016/j.ccr.2006.12.013
   PubMed Web of Science ®Google Scholar
• Ravindran J, Gupta N, Agrawal M, Bala Bhaskar AS, Lakshmana Rao PV. Modulation of ROS/MAPK signaling pathways by okadaic acid leads to cell death via, mitochondrial mediated caspase-dependent mechanism. Apoptosis 2011; 16:145-61; PMID:21082355; http://dx.doi.org/10.1007/s10495-010-0554-0
   PubMed Web of Science ®Google Scholar
• Liu WH, Cheng YC, Chang LS. ROS-mediated p38alpha MAPK activation and ERK inactivation responsible for upregulation of Fas and FasL and autocrine Fas-mediated cell death in Taiwan cobra phospholipase A(2)-treated U937 cells. J Cell Physiol 2009; 219:642-51; PMID:19180563; http://dx.doi.org/10.1002/jcp.21713
   PubMed Web of Science ®Google Scholar
• Bu HQ, Cai K, Shen F, Bao XD, Xu Y, Yu F, Pan HQ, Chen CH, Du ZJ, Cui JH. Induction of apoptosis by capsaicin in hepatocellular cancer cell line SMMC-7721 is mediated through ROS generation and activation of JNK and p38 MAPK pathways. Neoplasma 2015; 62:582-91; PMID:25997958; http://dx.doi.org/10.4149/neo_2015_070
   PubMed Web of Science ®Google Scholar
• Kumari G, Ulrich T, Krause M, Finkernagel F, Gaubatz S. Induction of p21CIP1 Protein and Cell Cycle Arrest after Inhibition of Aurora B Kinase Is Attributed to Aneuploidy and Reactive Oxygen Species. J Biol Chem 2014; 289:16072-84; PMID:24782314; http://dx.doi.org/10.1074/jbc.M114.555060
   PubMed Web of Science ®Google Scholar
• Kumari G, Ulrich T, Gaubatz S. A role for p38 in transcriptional elongation of p21 (CIP1) in response to Aurora B inhibition. Cell Cycle 2013; 12:2051-60; PMID:23759594; http://dx.doi.org/10.4161/cc.25100
   PubMed Web of Science ®Google Scholar
• Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, et al. Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res 2015; 75:181-93; PMID:25398437; http://dx.doi.org/10.1158/0008-5472.CAN-14-2405
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Kelly KR, Ecsedy J, Mahalingam D, Nawrocki ST, Padmanabhan S, Giles FJ, Carew JS. Targeting aurora kinases in cancer treatment. Curr Drug Targets 2011; 12:2067-78; PMID:21777198; http://dx.doi.org/10.2174/138945011798829410
   PubMed Web of Science ®Google Scholar
• Silva VC, Cassimeris L. Stathmin and microtubules regulate mitotic entry in HeLa cells by controlling activation of both Aurora kinase A and Plk1. Mol Biol Cell 2013; 24:3819-31; PMID:24152729; http://dx.doi.org/10.1091/mbc.E13-02-0108
   PubMed Web of Science ®Google Scholar
• Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res 2013; 19:1717-28; PMID:23403633; http://dx.doi.org/10.1158/1078-0432.CCR-12-2383
   PubMed Web of Science ®Google Scholar
• Mannino M, Gomez-Roman N, Hochegger H, Chalmers AJ. Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics. Stem Cell Res 2014; 13:135-43; PMID:24879067; http://dx.doi.org/10.1016/j.scr.2014.05.001
   PubMed Web of Science ®Google Scholar
• Marxer M, Ma HT, Man WY, Poon RY. p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases. Oncogene 2014; 33:3550-60; PMID:23955083; http://dx.doi.org/10.1038/onc.2013.325
   PubMed Web of Science ®Google Scholar
• Steigemann P, Wurzenberger C, Schmitz MH, Held M, Guizetti J, Maar S, Gerlich DW. Aurora B-mediated abscission checkpoint protects against tetraploidization. Cell 2009; 136:473-84; PMID:19203582; http://dx.doi.org/10.1016/j.cell.2008.12.020
   PubMed Web of Science ®Google Scholar
• Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, et al. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res 2010; 16:3171-81; PMID:20423983; http://dx.doi.org/10.1158/1078-0432.CCR-09-3171
   PubMed Web of Science ®Google Scholar
• Portella G, Passaro C, Chieffi P. Aurora B: a new prognostic marker and therapeutic target in cancer. Curr Med Chem 2011; 18:482-96; PMID:21143115; http://dx.doi.org/10.2174/092986711794480203
   PubMed Web of Science ®Google Scholar
• Fu S, Hu W, Kavanagh JJ, Bast RC, Jr. Targeting Aurora kinases in ovarian cancer. Exp Opin Ther Targets 2006; 10:77-85; PMID:16441230; http://dx.doi.org/10.1517/14728222.10.1.77
   PubMed Web of Science ®Google Scholar
• Green MR, Woolery JE, Mahadevan D. Update on Aurora Kinase Targeted Therapeutics in Oncology. Exp Opin Drug discov 2011; 6:291-307; PMID:21556291; http://dx.doi.org/10.1517/17460441.2011.555395
   PubMed Web of Science ®Google Scholar
• Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, et al. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther 2015; 14:2687-99; PMID:26443806; http://dx.doi.org/10.1158/1535-7163.MCT-15-0096
   PubMed Web of Science ®Google Scholar
• Sun JM, Yang LN, Xu H, Chang B, Wang HY, Yang G. Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells. Am J Cancer Res 2015; 5:1133-45; PMID:26045992
   PubMed Web of Science ®Google Scholar
• Cheok CF, Kua N, Kaldis P, Lane DP. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ 2010; 17:1486-500; PMID:20203688; http://dx.doi.org/10.1038/cdd.2010.18
   PubMed Web of Science ®Google Scholar
• Kretzner L, Scuto A, Dino PM, Kowolik CM, Wu J, Ventura P, Jove R, Forman SJ, Yen Y, Kirschbaum MH. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res 2011; 71:3912-20; PMID:21502403; http://dx.doi.org/10.1158/0008-5472.CAN-10-2259
   PubMed Web of Science ®Google Scholar
• Park JS, Carter S, Reardon DB, Schmidt-Ullrich R, Dent P, Fisher PB. Roles for basal and stimulated p21(Cip-1/WAF1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells. Mol Biol Cell 1999; 10:4231-46; PMID:10588655; http://dx.doi.org/10.1091/mbc.10.12.4231
   PubMed Web of Science ®Google Scholar
• Grossi V, Peserico A, Tezil T, Simone C. p38alpha MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. World J Gastroenterol 2014; 20:9744-58; PMID:25110412; http://dx.doi.org/10.3748/wjg.v20.i29.9744
   PubMed Web of Science ®Google Scholar
• Koul HK, Pal M, Koul S. Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes Cancer 2013; 4:342-59; PMID:24349632; http://dx.doi.org/10.1177/1947601913507951
   PubMedGoogle Scholar
• Tormos AM, Talens-Visconti R, Nebreda AR, Sastre J. p38 MAPK: a dual role in hepatocyte proliferation through reactive oxygen species. Free Radical Res 2013; 47:905-16; PMID:23906070; http://dx.doi.org/10.3109/10715762.2013.821200
   PubMed Web of Science ®Google Scholar
• Kuma Y, Sabio G, Bain J, Shpiro N, Marquez R, Cuenda A. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem 2005; 280:19472-9; PMID:15755732; http://dx.doi.org/10.1074/jbc.M414221200
   PubMed Web of Science ®Google Scholar
• He D, Zhao XQ, Chen XG, Fang Y, Singh S, Talele TT, Qiu HJ, Liang YJ, Wang XK, Zhang GQ, et al. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells. PloS One 2013; 8:e54181; PMID:23349819; http://dx.doi.org/10.1371/journal.pone.0054181
   PubMed Web of Science ®Google Scholar
• Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Hickey E, Klaus B, Madwed J, Moriak M, Moss N, et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J Med Chem 2002; 45:2994-3008; PMID:12086485; http://dx.doi.org/10.1021/jm020057r
   PubMed Web of Science ®Google Scholar